These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11485052)

  • 1. An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice.
    Belzung C; Le Guisquet AM; Barreau S; Calatayud F
    Behav Pharmacol; 2001 Jun; 12(3):151-62. PubMed ID: 11485052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone.
    Griebel G; Perrault G; Sanger DJ
    Psychopharmacology (Berl); 1998 Jul; 138(1):55-66. PubMed ID: 9694527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635.
    Bagdy G; Graf M; Anheuer ZE; Modos EA; Kantor S
    Int J Neuropsychopharmacol; 2001 Dec; 4(4):399-408. PubMed ID: 11806866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone.
    Harada K; Aota M; Inoue T; Matsuda R; Mihara T; Yamaji T; Ishibashi K; Matsuoka N
    Eur J Pharmacol; 2006 Dec; 553(1-3):171-84. PubMed ID: 17074317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment.
    Harro J; Põld M; Vasar E
    Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):62-7. PubMed ID: 2314484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of serotonergic mechanisms involved in the behavioural inhibition induced by 5-hydroxytryptophan in a modified light-dark test in mice.
    Artaiz I; Zazpe A; Del Río J
    Behav Pharmacol; 1998 Mar; 9(2):103-12. PubMed ID: 10065930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice.
    Da-Rocha MA; Puech AJ; Thiébot MH
    J Psychopharmacol; 1997; 11(3):211-8. PubMed ID: 9305412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Behavioral and neurochemical changes following predatory stress in mice.
    Belzung C; El Hage W; Moindrot N; Griebel G
    Neuropharmacology; 2001 Sep; 41(3):400-8. PubMed ID: 11522332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the elevated plus-maze the anxiolytic-like effects of the 5-HT(1A) agonist, 8-OH-DPAT, but not the anxiogenic-like effects of the 5-HT(1A) partial agonist, buspirone, are blocked by the 5-HT1A antagonist, WAY 100635.
    Collinson N; Dawson GR
    Psychopharmacology (Berl); 1997 Jul; 132(1):35-43. PubMed ID: 9272757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: an ethological analysis.
    Silva RC; Brandão ML
    Pharmacol Biochem Behav; 2000 Feb; 65(2):209-16. PubMed ID: 10672971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute anxiogenic-like effects of selective serotonin reuptake inhibitors are attenuated by the benzodiazepine diazepam in BALB/c mice.
    Birkett MA; Shinday NM; Kessler EJ; Meyer JS; Ritchie S; Rowlett JK
    Pharmacol Biochem Behav; 2011 Jun; 98(4):544-51. PubMed ID: 21397628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nucleus incertus contributes to an anxiogenic effect of buspirone in rats: Involvement of 5-HT1A receptors.
    Kumar JR; Rajkumar R; Lee LC; Dawe GS
    Neuropharmacology; 2016 Nov; 110(Pt A):1-14. PubMed ID: 27436722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anxiogenic-like effects induced by stimulation of dopamine receptors.
    Simon P; Panissaud C; Costentin J
    Pharmacol Biochem Behav; 1993 Jul; 45(3):685-90. PubMed ID: 8101381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety.
    Griebel G; Perrault G; Sanger DJ
    Neuropharmacology; 1997 Jun; 36(6):793-802. PubMed ID: 9225307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone.
    Moser PC
    Psychopharmacology (Berl); 1989; 99(1):48-53. PubMed ID: 2528779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiolytic effect of berberine on exploratory activity of the mouse in two experimental anxiety models: interaction with drugs acting at 5-HT receptors.
    Peng WH; Wu CR; Chen CS; Chen CF; Leu ZC; Hsieh MT
    Life Sci; 2004 Oct; 75(20):2451-62. PubMed ID: 15350820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.
    Rupniak NM; Carlson EC; Harrison T; Oates B; Seward E; Owen S; de Felipe C; Hunt S; Wheeldon A
    Neuropharmacology; 2000 Jun; 39(8):1413-21. PubMed ID: 10818257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice.
    Norcross M; Mathur P; Enoch AJ; Karlsson RM; Brigman JL; Cameron HA; Harvey-White J; Holmes A
    Psychopharmacology (Berl); 2008 Oct; 200(3):413-24. PubMed ID: 18594797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.
    Bruins Slot LA; Bardin L; Auclair AL; Depoortere R; Newman-Tancredi A
    Behav Pharmacol; 2008 Mar; 19(2):145-52. PubMed ID: 18332679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders.
    Stemmelin J; Cohen C; Terranova JP; Lopez-Grancha M; Pichat P; Bergis O; Decobert M; Santucci V; Françon D; Alonso R; Stahl SM; Keane P; Avenet P; Scatton B; le Fur G; Griebel G
    Neuropsychopharmacology; 2008 Feb; 33(3):574-87. PubMed ID: 17460614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.